Valuation: Amgen Inc.

Market Cap 252B 1,368B 226B 208B 188B 352B 23,922B 358B 2,475B 994B 12,584B 946B 925B 39,684B P/E 2026 *
29.6x
P/E 2027 * 26.3x
Enterprise Value 293B 1,593B 263B 242B 219B 409B 27,849B 417B 2,881B 1,157B 14,649B 1,101B 1,077B 46,198B EV / Sales 2026 *
7.53x
EV / Sales 2027 * 7.11x
Free-Float
99.77%
Yield 2026 *
2.16%
Yield 2027 * 2.29%
1 day+12.97%
1 week+15.70%
1 month+17.91%
3 months+30.45%
6 months+48.49%
Current year+38.22%
1 week 83.79
Extreme 83.79
91.74
1 month 71.09
Extreme 71.09
91.74
Current year 48.4
Extreme 48.4
91.74
1 year 48.4
Extreme 48.4
91.74
3 years 45.12
Extreme 45.12
91.74
5 years 37.52
Extreme 37.52
91.74
10 years 15.78
Extreme 15.780356
91.74
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Chief Tech/Sci/R&D Officer 57 31/05/2023
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+12.97%+15.70% - - 252B
+3.19%+11.31%+64.28%+155.66% 1,263B
-0.73%+3.56%+44.65%+83.74% 658B
+1.41%+3.24%+35.25%+106.98% 521B
+0.42%+3.20%+55.81%+69.71% 391B
+2.18%+2.93%+73.90%+45.38% 369B
+1.12%+4.52%+34.76%+57.00% 307B
+6.96%+8.86%+11.95%+35.06% 290B
+1.15%+6.09%+56.15%+78.66% 252B
+3.06%+9.38%+42.48%+112.84% 212B
Average +3.17%+5.90%+46.58%+82.78% 473.55B
Weighted average by Cap. +2.62%+6.60%+50.51%+99.19%

Financials

2026 *2027 *
Net sales 38.97B 212B 34.91B 32.11B 29.09B 54.38B 3,701B 55.4B 383B 154B 1,947B 146B 143B 6,139B 40.4B 219B 36.18B 33.28B 30.15B 56.37B 3,836B 57.42B 397B 159B 2,018B 152B 148B 6,363B
Net income 8.56B 46.48B 7.67B 7.05B 6.39B 11.94B 813B 12.17B 84.08B 33.75B 427B 32.12B 31.44B 1,348B 9.44B 51.25B 8.45B 7.78B 7.05B 13.17B 896B 13.42B 92.73B 37.22B 471B 35.42B 34.67B 1,487B
Net Debt 41.36B 225B 37.04B 34.07B 30.87B 57.7B 3,927B 58.78B 406B 163B 2,066B 155B 152B 6,514B 35.3B 192B 31.62B 29.08B 26.35B 49.26B 3,352B 50.18B 347B 139B 1,763B 132B 130B 5,561B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
30/10/26 R$91.17 +2.95% 252
29/10/26 R$88.56 +2.68% 379
28/10/26 R$86.25 +1.20% 1,316
27/10/26 R$85.23 -0.71% 65
26/10/26 R$85.84 +8.93% 415
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
466.01USD
Average target price
397.32USD
Spread / Average Target
-14.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.